SCHEMBL20964704

SCHEMBL20964704

Cc1noc(C)c1CSc1ncccc1C(=O)N1CCN(c2cccc([N+](=O)[O-])c2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 10/20 0.59
LMNA P02545 6/20 0.59
ALDH1A1 P00352 5/20 0.59
TSHR P16473 3/20 0.59
MAPT P10636 9/20 0.55
NPC1 O15118 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HTT P42858 4/20 0.47
TDP1 Q9NUW8 2/20 0.47
SLC6A9 P48067 2/20 0.45
SLC6A5 Q9Y345 2/20 0.45
KDM4E B2RXH2 1/20 0.43
MGLL Q99685 1/20 0.43
KMT2A Q03164 2/20 0.43
MAPK1 P28482 2/20 0.43
MEN1 O00255 1/20 0.43
PKM P14618 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
AR P10275 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20964561 0.92 MAPT (0.66) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20964660 0.89 SMN1; SMN2 (0.63) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20964627 0.88 LMNA (0.62) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL19744985 0.88 SMN1; SMN2 (0.62) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20964607 0.87 MAPT (0.53) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20965422 0.87 SMN1; SMN2 (0.60) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20964667 0.85 NPC1 (0.68) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20965350 0.83 SMN1; SMN2 (0.49) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20964609 0.81 ALDH1A1 (0.61) SMN1; SMN2LMNAALDH1A1TSHRMAPT
SCHEMBL20964632 0.80 SMN1; SMN2 (0.57) SMN1; SMN2LMNAALDH1A1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 SMN1; SMN2 263/4885LMNA 1413/4885ALDH1A1 141/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 SMN1; SMN2 2477/4885LMNA 897/4885ALDH1A1 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.